company background image
BIO logo

Bio-Rad Laboratories NYSE:BIO Stock Report

Last Price

US$333.43

Market Cap

US$9.5b

7D

-3.1%

1Y

-28.7%

Updated

18 Mar, 2024

Data

Company Financials +

Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$9.5b

BIO Stock Overview

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.

BIO fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Bio-Rad Laboratories, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Rad Laboratories
Historical stock prices
Current Share PriceUS$333.43
52 Week HighUS$494.05
52 Week LowUS$261.59
Beta0.87
1 Month Change-2.08%
3 Month Change5.79%
1 Year Change-28.68%
3 Year Change-42.51%
5 Year Change8.54%
Change since IPO12,947.26%

Recent News & Updates

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Dec 17
Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Recent updates

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Dec 17
Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Nov 20
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Oct 02
At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Aug 21
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Jul 30
Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 04
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

May 23
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

May 01
A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Apr 04
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs reports Q4 2022 results

Feb 16

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Feb 10
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 20
Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Dec 08
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oct 14
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Sep 02
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 25
When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jul 04
Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

May 02
Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

Bio-Rad Offers Value If You Look

Mar 28

Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook

Dec 25

Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Dec 10
Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

What Is Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Share Price Doing?

Aug 25
What Is Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Share Price Doing?

Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

May 11
Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Shareholder Returns

BIOUS Life SciencesUS Market
7D-3.1%-1.5%0.5%
1Y-28.7%5.7%29.0%

Return vs Industry: BIO underperformed the US Life Sciences industry which returned 5.9% over the past year.

Return vs Market: BIO underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is BIO's price volatile compared to industry and market?
BIO volatility
BIO Average Weekly Movement3.8%
Life Sciences Industry Average Movement7.2%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BIO has not had significant price volatility in the past 3 months.

Volatility Over Time: BIO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19528,030Norman Schwartzhttps://www.bio-rad.com

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Bio-Rad Laboratories, Inc. Fundamentals Summary

How do Bio-Rad Laboratories's earnings and revenue compare to its market cap?
BIO fundamental statistics
Market capUS$9.50b
Earnings (TTM)-US$637.32m
Revenue (TTM)US$2.67b

3.6x

P/S Ratio

-14.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIO income statement (TTM)
RevenueUS$2.67b
Cost of RevenueUS$1.24b
Gross ProfitUS$1.43b
Other ExpensesUS$2.07b
Earnings-US$637.32m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-22.35
Gross Margin53.56%
Net Profit Margin-23.86%
Debt/Equity Ratio13.6%

How did BIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.